Clinical efficacy of small dose of antithymocyte globulin and zenapax in kidney transplant recipients
- VernacularTitle:小剂量兔抗人胸腺细胞免疫球蛋白和赛尼哌在肾移植诱导治疗中的应用效果
- Author:
Guo-Hai SHI
;
Xiang-Hui WANG
;
Da XU
;
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Antithymocyte globulin;
Zenapax;
Graft rejection
- From:
Chinese Journal of Urology
2000;0(12):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of small dose of antithymocyte globulin(ATG)and zenapax in the induction therapy for kidney transplant recipients.Methods A series of 150 cadaver-donor kidney transplant recipients were randomly divided to 3 groups,ie,small dose of ATG group(total dose,2.1 -3.0 mg/kg;n=72),zenapax group(50mg,on the first and 14th d after operation;n=15)and controls without induction therapy(n=63).Follow-up was 6 months.The rates of acute rejection,delayed graft func- tion(DGF)and pulmonary infection were statistically compared among the 3 groups.Results During a 6-month period,in ATG,zenapax and control groups,acute rejection episodes occurred in 4 cases(5.5%), 1(6.7%)and 10(15.9%),respectively;DGF occurred in 3(4.2%),0 and 8(12.7%),respectively;pul- monary infection occurred in 4(5.1%),1(6.7%)and 3(4.8%),respectively;leucocytopenia occurred in 3(4.2%),1(6.7%)and 5(7.9%),respectively;thrombocytopenia occurred in 2(2.8%),1(6.7%)and 5(7.9%),respectively.Conclusions In the early stage of kidney transplantation,small dose of ATG and zenapax can be the optimal choice for induction therapy.
